Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Preferred Developer Status

17 Jan 2008 07:00

CareCapital Group plc17 January 2008 Embargoed: for release at 07.00, 17 January 2008 CareCapital Group Plc ("CareCapital") Investment and Development Programme in the UK Successful bid on two Medical Centres CareCapital, the AIM listed healthcare real estate company, announces that ithas been selected as the preferred developer for the provision of a £4.1 millionnew build medical centre in Heswall and a new medical centre in West Wirralexceeding £5 million. The 1,556 sq metre Heswall project will accommodate six GPs together with arange of support services. The current development programme anticipatesconstruction starting before the end of 2008 with the new facility becomingoperational in December 2009. The 2,241 sq metre West Wirral development will house a ten GP Practice andancillary medical facilities. The development programme is on a similar timelineto the Heswall project. Paul Stacey, Chief Executive of CareCapital commented: "It is very pleasing tohave been selected as preferred developer on these two exciting projects. We arelooking forward to working with all the stakeholders, including the Doctors andthe Primary Care Trust, to bring the developments to fruition in the shortestpossible timespan. These projects further strengthen our current businesspipeline; as the Company continues to expand its investment and developmentprogramme in both the UK and Germany." -ends- For further information please visit www.carecapital.co.uk or contact: Paul Stacey, Managing Director Lindsay Mair, Director Simon Hudson,Shareen Courtney, Marketing - Corporate Finance Paul Youens, Paul Young CareCapital Group Plc Daniel Stewart & Co. Plc Tavistock Communications Tel: 020 7034 1949 Tel: 020 7776 6550 Tel: 020 7920 3150 or 07966 477256 pstacey@carecapital.co.uk lindsay.mair@danielstewart.co.uk shudson@tavistock.co.ukscourtney@carecapital.co.uk pyouens@tavistock.co.uk pyoung@tavistock.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility
1st Mar 20232:54 pmRNSSecured Convertible Note Facility & other matters
1st Mar 20232:05 pmRNSSecond Price Monitoring Extn
1st Mar 20232:00 pmRNSPrice Monitoring Extension
27th Jan 20234:53 pmEQSHardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date
18th Jan 20232:00 pmRNSOperational update
17th Jan 20233:10 pmEQSHardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV
30th Dec 20221:00 pmRNSTotal Voting Rights
30th Dec 20229:24 amRNSDirector/PDMR Shareholding
29th Dec 20223:12 pmRNSDirector/PDMR Shareholding
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 202212:40 pmRNSSecond Price Monitoring Extn
23rd Dec 202212:35 pmRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSEquity Subscription and Issue of Warrants
1st Dec 20227:00 amRNSIssue of Equity
28th Nov 20227:00 amRNSStudy showcases the potential superiority of LIGHT
3rd Nov 20223:20 pmRNSInvestor / Analyst Event Update
31st Oct 20225:00 pmRNSTotal Voting Rights
27th Oct 20227:31 amRNSPresentation highlights superiority of LIGHT
21st Oct 20227:00 amRNSNotice of Investor / Analyst Event
18th Oct 20227:00 amRNSEquity Subscription and Issue of Warrants
30th Sep 20225:00 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSInterim Results
29th Sep 20227:15 amEQSHardman & Co Research on Advanced Oncotherapy: Major milestone achieved
27th Sep 202210:30 amRNSLIGHT accelerator fully operational
31st Aug 20225:00 pmRNSTotal Voting Rights
23rd Aug 20223:09 pmRNSUpdate re admission of Subscription Shares
19th Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
17th Aug 20225:30 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
29th Jul 20224:30 pmRNSResult of AGM
7th Jul 202212:30 pmRNSHolding(s) in Company
30th Jun 20225:00 pmRNSTotal Voting Rights
30th Jun 20229:00 amRNSFinal results for the year ended 31 December 2021
28th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
13th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
31st May 20225:00 pmRNSTotal Voting Rights
27th May 202212:17 pmRNSHolding(s) in Company
11th May 20227:00 amRNSLIGHT system potential in delivering FLASH
29th Apr 20225:00 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNSVideo showcases progress on LIGHT system process
26th Apr 20227:00 amRNSOperational update
22nd Apr 20227:00 amRNSUpdate re admission of Subscription Shares
19th Apr 20224:05 pmRNSUpdate re admission of Subscription Shares
12th Apr 20227:13 amRNSEquity Subscription and Issue of Warrants
31st Mar 20225:00 pmRNSTotal Voting Rights
25th Mar 20229:30 amRNS£2m Subscription, Add'l Loan and Issue of Warrants
14th Mar 20227:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO) - LIGHT: regulatory update
4th Mar 20229:00 amRNSDirector/PDMR Notification
3rd Mar 20226:13 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.